[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Whitehawk Therapeutics Inc (WHWK)

Whitehawk Therapeutics Inc (WHWK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 199,643
  • Shares Outstanding, K 47,197
  • Annual Sales, $ 7,150 K
  • Annual Income, $ -20,600 K
  • EBIT $ -114 M
  • EBITDA $ -116 M
  • 60-Month Beta 0.57
  • Price/Sales 27.74
  • Price/Cash Flow N/A
  • Price/Book 1.45

Options Overview Details

View History
  • Implied Volatility 436.88% (-54.11%)
  • Historical Volatility 70.99%
  • IV Percentile 82%
  • IV Rank 57.77%
  • IV High 721.17% on 03/06/26
  • IV Low 47.99% on 10/23/25
  • Expected Move (DTE 22) 0.00 (0.00%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 8
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 1.06
  • Today's Open Interest 70
  • Open Int (30-Day) 316
  • Expected Range 4.23 to 4.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.36
  • Number of Estimates 3
  • High Estimate $-0.29
  • Low Estimate $-0.45
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.15 +36.67%
on 03/27/26
4.40 -2.16%
on 04/22/26
+0.65 (+17.95%)
since 03/23/26
3-Month
2.60 +65.58%
on 01/29/26
4.48 -3.90%
on 03/10/26
+1.60 (+59.44%)
since 01/23/26
52-Week
1.39 +209.71%
on 04/25/25
4.48 -3.90%
on 03/10/26
+2.76 (+179.55%)
since 04/23/25

Most Recent Stories

More News
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026

Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform

WHWK : 4.20 (-0.71%)
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series

MORRISTOWN, N.J. , April 16, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor...

WHWK : 4.20 (-0.71%)
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026

MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets

WHWK : 4.20 (-0.71%)
Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

MORRISTOWN, N.J. , March 17, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor...

WHWK : 4.20 (-0.71%)
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

Actively recruiting Phase 1 trials for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 and MUC16-targeted ADC HWK-016

WHWK : 4.20 (-0.71%)
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences

MORRISTOWN, N.J. , Feb. 26, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology...

WHWK : 4.20 (-0.71%)
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016

Actively recruiting Phase 1 trial for PTK7-targeted antibody-drug conjugate (ADC) HWK-007

WHWK : 4.20 (-0.71%)
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer

Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic

WHWK : 4.20 (-0.71%)
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

MORRISTOWN, N.J. , Nov. 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently...

WHWK : 4.20 (-0.71%)
AI-Powered Platforms Scale as Preventive Care and Biomarker Testing Converge

VANCOUVER – Baystreet.ca News Commentary – Healthcare providers are prioritizing preventive care strategies as nearly 58% now integrate biomarker testing into early wellness indicators [1], a shift...

HIMS : 29.04 (+0.10%)
TEM : 52.29 (-5.80%)
WHWK : 4.20 (-0.71%)
BFLY : 5.37 (-2.89%)
ALEN-U.CN : 0.9800 (unch)

Business Summary

Aadi Bioscience Inc. is a clinical-stage biopharmaceutical company. It focuses on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes. Aadi Bioscience Inc., formerly known as Aerpio Pharmaceuticals Inc., is based in LOS ANGELES.

See More

Key Turning Points

3rd Resistance Point 4.58
2nd Resistance Point 4.49
1st Resistance Point 4.36
Last Price 4.20
1st Support Level 4.14
2nd Support Level 4.05
3rd Support Level 3.92

See More

52-Week High 4.48
Last Price 4.20
Fibonacci 61.8% 3.30
Fibonacci 50% 2.93
Fibonacci 38.2% 2.57
52-Week Low 1.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.